Best Practice and Research. Clinical Haematology 
This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.
This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.Editorial Board / Aims & Scope
Publication date: June 2018Source: Best Practice & Research Clinical Haematology, Volume 31, Issue 2Author(s): (Source: Best Practice and Research Clinical Haematology)
Source: Best Practice and Research Clinical Haematology - July 5, 2018 Category: Hematology Source Type: research
CAR T cells, immunologic and cellular therapies in hematologic malignancies
Publication date: June 2018Source: Best Practice & Research Clinical Haematology, Volume 31, Issue 2Author(s): Renier Brentjens, Marco L. Davila (Source: Best Practice and Research Clinical Haematology)
Source: Best Practice and Research Clinical Haematology - July 5, 2018 Category: Hematology Source Type: research
Pre-clinical development of chimeric antigen receptor T-cell immunotherapy: Implications of design for efficacy and safety
Publication date: June 2018Source: Best Practice & Research Clinical Haematology, Volume 31, Issue 2Author(s): Leena Halim, Adam Ajina, John MaherAbstractFollowing the landmark approvals by the United States Food and Drug Administration, the adoptive transfer of CD19-directed chimeric antigen receptor (CAR) T-cells has now entered mainstream clinical practice for patients with chemotherapy-resistant or refractory B-cell malignancies. These approvals have followed on from a prolonged period of pre-clinical evaluation, informing the design of clinical trials that have demonstrated unprecedented efficacy in this difficult to ...
Source: Best Practice and Research Clinical Haematology - July 5, 2018 Category: Hematology Source Type: research
GMP CAR-T cell production
This article reviews the issues that must be addressed in order to achieve this goal. It includes the manufacturing infrastructure, the regulatory environment, practical aspects of production, and the costs involved. (Source: Best Practice and Research Clinical Haematology)
Source: Best Practice and Research Clinical Haematology - July 5, 2018 Category: Hematology Source Type: research
CAR T cell therapy for B-cell lymphomas
Publication date: June 2018Source: Best Practice & Research Clinical Haematology, Volume 31, Issue 2Author(s): Julio C. Chavez, Frederick L. LockeAbstractB-cell non-Hodgkin's lymphoma (NHLs)is a very heterogonous malignancy with diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL) as the most common subtypes. Standard treatment with anti-CD20 based chemoimmunotherapy is usually very effective for disease control. However a significant proportion of patients with high-risk features (double hit lymphoma, transformed lymphomas or early relapses) will become refractory to standard therapies and will have limited ...
Source: Best Practice and Research Clinical Haematology - July 5, 2018 Category: Hematology Source Type: research
CARs and other T cell therapies for MM: The clinical experience
Publication date: June 2018Source: Best Practice & Research Clinical Haematology, Volume 31, Issue 2Author(s): Sophia Danhof, Michael Hudecek, Eric L. SmithAbstractHarnessing the endogenous immune system to eliminate malignant cells has long been an intriguing approach. After considerable success in the treatment of B-cell acute lymphoblastic leukemia, chimeric antigen receptor (CAR)-modified T cells have entered early clinical evaluation in the field of multiple myeloma (MM). The choice of suitable non-CD19 target antigens is challenging and a variety of myeloma-associated surface molecules have been under preclinical inv...
Source: Best Practice and Research Clinical Haematology - July 5, 2018 Category: Hematology Source Type: research
Toxicities associated with immunotherapies for hematologic malignancies
Publication date: June 2018Source: Best Practice & Research Clinical Haematology, Volume 31, Issue 2Author(s): Mark B. Leick, Marcela V. MausAbstractImmunotherapy has generated tremendous hope for patients with cancer that is refractory to standard approaches. Hematologic malignancies have taken the lead in harnessing the most recent advances in cell-based immunotherapies, such as CAR T cells, and some patients have achieved durable remissions. However, these T-cell-engaging therapies are associated with a new set of toxicities which need to be managed by caretakers, oncologists, nurses, and healthcare staff. In this revie...
Source: Best Practice and Research Clinical Haematology - July 5, 2018 Category: Hematology Source Type: research
The unique biology and treatment of primary mediastinal B-cell lymphoma
Publication date: Available online 3 July 2018Source: Best Practice & Research Clinical HaematologyAuthor(s): Alessandro Broccoli, Pier Luigi ZinzaniAbstractThe unique biological features of primary mediastinal large B-cell lymphoma are offering suggestions for the development and application of innovative drugs in patients who do not respond to first-line regimens or relapse. This lymphoma, in fact, is characterised by high rates of curability with standard anthracycline-containing chemoimmunotherapy regimens, but still displays a severe prognosis if adequate responses are not rapidly achieved or if the disease recurs. Ra...
Source: Best Practice and Research Clinical Haematology - July 5, 2018 Category: Hematology Source Type: research
Extranodal NK/T-cell lymphoma: updates in biology and management strategies
Publication date: Available online 3 July 2018Source: Best Practice & Research Clinical HaematologyAuthor(s): Motoko Yamaguchi, Masahiko Oguchi, Ritsuro SuzukiAbstractExtranodal NK/T-cell lymphoma, nasal type (ENKL), is a rare lymphoma subtype of peripheral T/NK-cell lymphoma that is very common in East Asia and Latin America. Two-thirds of patients have localized disease in the nasal cavity or adjacent sites. Large retrospective studies have revealed the clinicopathologic features of ENKL patients, identified risk factors for short survival time, and developed prognostic models. Next-generation sequencing studies have pro...
Source: Best Practice and Research Clinical Haematology - July 5, 2018 Category: Hematology Source Type: research
Monitoring Clinical Outcomes in Aggressive B-cell Lymphoma: From Imaging Studies to Circulating Tumor DNA
Publication date: Available online 3 July 2018Source: Best Practice & Research Clinical HaematologyAuthor(s): Christopher Melani, Wyndham H. Wilson, Mark RoschewskiAbstractRecent guidelines have de-emphasized the role of routine surveillance computed tomography (CT) scans for diffuse large B-cell lymphoma (DLBCL) patients who achieve a complete response to front-line therapy. This shift in practice recommendations was prompted by retrospective studies that failed to demonstrate clear clinical utility for surveillance CT in unselected DLBCL patients. Controversy remains, however, over the role of routine surveillance CT in ...
Source: Best Practice and Research Clinical Haematology - July 5, 2018 Category: Hematology Source Type: research
CAR T Cell Therapy for B-cell Lymphomas
Publication date: Available online 11 April 2018 Source:Best Practice & Research Clinical Haematology Author(s): Julio C. Chavez, Frederick L. Locke B-cell non-Hodgkin’s lymphoma (NHLs)is a very heterogonous malignancy with diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL) as the most common subtypes. Standard treatment with anti-CD20 based chemoimmunotherapy is usually very effective for disease control. However a significant proportion of patients with high-risk features (double hit lymphoma, transformed lymphomas or early relapses) will become refractory to standard therapies and will have...
Source: Best Practice and Research Clinical Haematology - April 12, 2018 Category: Hematology Source Type: research
GMP CAR-T cell production
This article reviews the issues that must be addressed in order to achieve this goal. It includes the manufacturing infrastructure, the regulatory environment, practical aspects of production, and the costs involved. (Source: Best Practice and Research Clinical Haematology)
Source: Best Practice and Research Clinical Haematology - April 2, 2018 Category: Hematology Source Type: research
Indolent lymphomas
Publication date: March 2018 Source:Best Practice & Research Clinical Haematology, Volume 31, Issue 1 Author(s): Brad Kahl (Source: Best Practice and Research Clinical Haematology)
Source: Best Practice and Research Clinical Haematology - April 2, 2018 Category: Hematology Source Type: research
CARs and other T cell therapies for MM: The clinical experience
Publication date: Available online 27 March 2018 Source:Best Practice & Research Clinical Haematology Author(s): Sophia Danhof, Michael Hudecek, Eric L. Smith Harnessing the endogenous immune system to eliminate malignant cells has long been an intriguing approach. After considerable success in the treatment of B-cell acute lymphoblastic leukemia, chimeric antigen receptor (CAR)-modified T cells have entered early clinical evaluation in the field of multiple myeloma (MM). The choice of suitable non-CD19 target antigens is challenging and a variety of myeloma-associated surface molecules have been under preclin...
Source: Best Practice and Research Clinical Haematology - April 2, 2018 Category: Hematology Source Type: research
Advances in the use of Natural Receptor- or Ligand-Based Chimeric Antigen Receptors (CARs) in haematologic malignancies
Publication date: Available online 27 March 2018 Source:Best Practice & Research Clinical Haematology Author(s): Joana M. Murad, David Graber, Charles L. Sentman Chimeric antigen receptors (CAR)-T cell therapy has recently made promising advances towards treatment of B-cell malignancies. This approach makes use of an antibody-derived single chain variable fragment (scFv)-based CAR to target the CD19 antigen. Currently scFvs are the most common strategy for creation of CARs, but tumor cells can also be targeted using non-antibody based approaches with designs focused on the interaction between natural receptors...
Source: Best Practice and Research Clinical Haematology - April 2, 2018 Category: Hematology Source Type: research
